Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review

We conducted a systematic review of Apremilast for treating immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis. Supplementary File 1. Search Strategy and Eligibility Criteria. Supplementary File 2. Complete List of References. Supplementary Table I. List of Included Studies, Characteristics of Psoriasis/Psoriasiform Eruption and Outcome after Apremilast Use. Supplementary Table II & III. Risk of Bias Assessment of Included Studies.